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Summary
Objective: To compare the ability of L-arginine (L-arg) analog nitric oxide synthase (NOS) inhibitors and isothioureas to restore the
interleukin-1 (IL-1) induced inhibition of proteoglycan (PG) synthesis in rat.
Methods: Chondrocytes beads and patellae were challenged with IL-1â in vitro and monitored for NO production and proteoglycan synthesis.
Rats injected with IL-1â in knee joints were monitored for NO2− +NO3− levels in joint tissues and ex-vivo 35S sulfate incorporation in patellae.
NOS inhibitors were either added to culture medium or injected concomittantly to IL-1â.
Results: Ability of NOS inhibitors to reduce NO2− levels decreased from chondrocytes beads to patellae. Partial restoration of PG synthesis
was restricted to L-arg analogs in patellae. After IL-1 injection, NO was produced from patella and synovium. L-arg analogs restored partly
PG synthesis when decreasing significantly NO2− +NO3− levels in synovial fluid. Isothioureas were ineffective.
Conclusions: NO accounts importantly for IL-1 induced inhibition of cartilage anabolism in rat. L-arg analog NOS inhibitors are more effective
than isothioureas in restoring PG synthesis and have chondroprotective potency when administered locally in diseased joint.
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It is now widely accepted that the inflammatory cytokine
interleukin-1 (IL-1), which is found at high levels in joint
effusions, plays a key role in cartilage damage during
rheumatoid arthritis (RA) and osteoarthritis (OA). Thus, IL-1
has been shown to inhibit the synthesis of cartilage matrix
molecules (proteoglycans, collagens) and to promote their
degradation by matrix metalloproteases.1 From there, it
has become obvious that the modulation of IL-1 effects has
pharmacological relevance and that this may be achieved
by modulating IL-1 itself or its effectors within target cells
such as radical species and products of the inducible genes
cyclooxygenase 2 (COX-2) and nitric oxide synthase II
(NOSII). In the last decade, compelling evidence has
emerged that the inorganic free radical nitric oxide (NO),
when produced in high amounts by NOSII, may be a major
effector of IL-1 effects on cartilage.2 Indeed, NO has been
shown to participate in: (i) inhibition of proteoglycan syn-
thesis in many species including humans; (ii) inhibition of
type II collagen synthesis in lapine chondrocytes; (iii) acti-
vation of metalloproteases in lapine and bovine chondro-
cytes; (iv) down-regulation of IL-1ra production by human
chondrocytes; (v) modulation of prostaglandin synthesis in
many species including humans; (vi) chondrocyte apop-
tosis [recently reviewed in 3]. In addition, NOS inhibitors
improved joint damage during experimental arthritis
although this effect may have been influenced by their382immunomodulatory properties in the course of the disease.
Based on the data mentioned above, inhibition of the
inducible NO pathway seems valuable for therapeutic inter-
vention. This may be achieved either by blocking NOSII
expression with signaling inhibitors such as cytokine sup-
pressing anti-inflammatory drugs or by decreasing NO
production at the enzyme level as with various NOS inhibi-
tors.4 The therapeutic insight offered by a pharmacological
modulation of NO in joint diseases remains a hazardous
question5 due to the following points: (i) the apparent
discrepancy between some data designing NO as protec-
tive or deleterious relative to cartilage catabolism, a finding
resulting possibly from species differences and/or differ-
ences in experimental conditions used; (ii) the variable
effect of NO on prostaglandin synthesis, depending poss-
ibly on the NO level and/or the cellular type; (iii) the inability
of NOS inhibitors to correct experimental arthritis when
given in established disease, suggesting a preventive
rather than a curative effect; (iv) the peculiarities of the
L-arginine-NO pathway itself including non receptor-
mediated effects, obligatory sparing of constitutive
enzymes, interplay of the natural substrate L-arginine with
many metabolic pathways; (v) the varying contribution of
NO within cartilage, depending on cartilage layers and/or
age; (vi) the respective contributions of joint tissues in
articular NO production, varying probably with the disease
state and/or between species; (vii) the uncertainty of taking
advantage from cartilage NOSII differences to selectively
inhibit NO production in joints. None the less, as most
drugs in clinical use in RA and OA are quite unable to
correct cartilage damage there is growing interest in study-
ing chondroprotective potencies of NOS inhibitors. We
compared the potencies of L-arginine (L-arg) analog
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proteoglycan synthesis. Rat was chosen due to its
relevance in experimental models of arthropathies. Both
in-vitro experiment with cartilage entities (patellae) and
chondrocytes cultured in alginate beads and in-vivo study
in the IL-1 induced arthritis model were performed.Materials and methods
ANIMALS AND MATERIALS
Wistar male rats (Charles River, France) were housed
according to guidelines for confinement of laboratory
animals and killed under dissociative anesthesia.
DMEM/Ham F12 and RPMI hepes 1640 medium, anti-
biotics and amino-acids supplements were from Gibco (Life
Technologies, France). Heat inactivated fetal calf serum
(FCS) was from Dutscher (France). Nw-monomethyl-L-
arginine (L-NMMA), Nw-iminoethyl-L-ornithine (L-NIO),
S-methylisothiourea (SMT) and S-aminoethyl isothiourea
were from Sigma or France-biochem (France). Human
recombinant interleukin-1â (IL-1â, 2×107 U/mg) was a gen-
erous gift from Rhoˆne-Poulenc-Rorer. Radiolabeled sodium
sulfate (100 mCi/mmol) was from Amersham (Les Ulis,
France).IN-VITRO CARTILAGE CULTURE
Chondrocytes from rat femoral head caps were
encapsulated in alginate beads and cultured for 1 week
before IL-1â challenge (25 U/ml) for two consecutive days
in low serum containing (2.5%) DMEM/Ham F12 medium,
in the presence or not of NOS inhibitors (10−6 to 10−3 M).
Patellae, free of surrounding tissues, were collected under
sterile conditions and subjected to IL-1â challenge (2.5 U/
ml) for two consecutive days in low serum containing
(2.5%) RPMI hepes 1640 medium, in the presence or not of
NOS inhibitor (10−6 to 10−3 M). Proteoglycan synthesis
was assessed at the end of incubation by a 3–4 h 35SO4
labeling followed by scintillation counting.EX-VIVO JOINT TISSUES CULTURE
At various times (1, 3, 6, 10, 24, 48 h) after a single
injection of 1 ìg IL-1â in rat knees, synovial fluid (SF) was
collected with filter paper pieces and both synovium
and patellae were further cultured for 48 h in low serumcontaining (2.5%) DMEM/Ham F12 medium to assess NO
production. NOS inhibitors were injected intra-articularly
(10−5 to 10−2 M solutions in a final volume of 50 ìl) at the
same time as IL-1â. After IL-1 injection, NO2− +NO3− levels
were measured in SF at 8 h and proteoglycan synthesis
was assessed by ex-vivo 35SO4 labeling in patellae at
day 2.NITRITE ASSAYS
In in-vitro experiments, NO2− levels were measured in
culture supernatants by using the Griess reaction and were
expressed as cumulated levels over the 48 h period. In
ex-vivo experiments, NO2− +NO3− levels were measured in
SF and supernatants by a spectrofluorimetric method using
2,3-diaminonaphtalene and NO3− reduction by bacterial
nitrate reductase.STATISTICS
IC50 were determined by linear regression. Data are
expressed as mean±SEM and were analyzed by ANOVA
followed by a Scheffe test. Differences with P<0.05 were
considered as significant.Table I
Effects of L-arginine analogs and isothioureas on rat articular cells stimulated with rhIL-1â
Batchs Chondrocytes beadsa Whole patellaeb
NO2− levels
IC50 (ìM)
35SO4 incorporation
% versus controlsc
NO2− levels
IC50 (ìM)
35SO4 incorporation
% versus controlsc
IL-1 ND 80(5) ND 73(4)
L-NMMA 60 96(8)*<X<102(11)* 400 88(1)*<X<96(11)*
L-NIO 25 87(5)*<X<102(6)* 24 82(5)*<X<102(6)*
SMT 2 88(7)<X<105(11)* 100 74(14)<X<75(7)
AETU 10 11(1)<X<71(7) 20 33(5)<X<72(12)
ND: not determined.
a
, 25 U/ml of rhIL-1â for 2 consecutive days.
b
, 2.5 U/ml of rhIL-1â for 2 consecutive days.
c
, X=corresponding value in 35SO4 labeling performed at 48 h (mean(SD)).
*, P £ 0.05 versus IL-1 treated (correcting effect only).Results
In in-vitro experiments, an apparent inverse relationship
between NO2− levels and proteoglycan (PG) synthesis was
noted after IL-1 challenge, in both chondrocytes and patel-
lae. Higher IL-1 doses were required to produce less
marked effects in chondrocytes beads than in patellae
(data not shown). When added to culture medium together
with IL-1, NOS inhibitors decreased NO2− levels with the
following rank order of potency: AETU>L-NIO>SMT>L-
NMMA (Table I). This effect was accompanied by a variable
restoration of PG synthesis which followed this rank order:
L-NIO‡ L-NMMA>>SMT>>AETU (Table I). In both cases,
NOS inhibitors were more effective in chondrocyte beads
than in patellae. D-NMMA was ineffective on both par-
ameters whereas L-arginine reversed L-NMMA effect at a
5-fold excess (data not shown). NOS inhibitors did not
significantly affect PG synthesis when added alone to
culture medium (data not shown) except AETU which was
cytotoxic at the two highest doses (confirmed by increased
LDH activity in culture medium).
384 J.-Y. Jouzeau et al.: Modulation of IL-1 effects by NOS inhibitors in rat cartilageIn-vivo experiments showed that single intra-articular (ia)
injection of IL-1â induced a time-dependent increase in
NO2− +NO3− levels in SF which was maximal at 10 h and
returned to basal level at 24 h. Joint tissues collected
concomittantly and maintained in ex-vivo cultures produced
high NO2− +NO3− levels, especially when taken in the first
3 h after IL-1 insult (data not shown). The decrease in PG
synthesis was maximal 48 h after IL-1 injection. When
administered at the same time as IL-1, L-NMMA signifi-
cantly reduced NO2− +NO3− levels in both SF and super-
natants from joint tissues cultures from the 10−4 M solution
and this was accompanied by a partial restoration of PG
synthesis for the 2 highest doses (Table II). In contrast,
SMT was ineffective on all above mentioned parameters
(Table II).Table II
Effects of intra-articular delivery of L-NMMA and SMT in the IL-1 arthritis model in rat
Batchsa NO2− +NO3− levels in SFb
% versus IL-1
35SO4 incorporation in patellaec
% versus controls
IL-1 treated (1 ìg/knee) 100±7 62±5
IL-1+L-NMMA 10−4 Md 64±11* 68±3
IL-1+L-NMMA 10−3 Md 53±8* 77±2*
IL-1+L-NMMA 10−2 Md 37±3* 76±2*
IL-1+SMT 10−4 Md 99±14 66±2
IL-1+SMT 10−3 Md 101±9 69±4
IL-1+SMT 10−2 Md 114±13 62±2
a
, 6 samples per group.
b
, Synovial fluid collected 8 h after IL-1 injection.
c
, Ex-vivo labeling 48 h after IL-1 injection.
d
, NOS inhibitor solution injected ia at the same time as IL-1 in a final volume of 50 ìl.
*, P£ 0.05 versus IL-1 treated.Discussion
Our in-vitro findings in the rat extend a previous work of
Ja¨rvinen et al.6 and suggest altogether that isolated
chondrocytes and cartilage explants (femoral heads and
patellae) produce high amounts of NO in response to IL-1
stimulation. It is noticeable that this exquisite sensitivity of
NOSII to respond to a single stimulus is common to
chondrocytes from all species tested so far including rabbit,
mouse, rat, cow and human and was observed in different
extracellular matrices.2,3 As IL-1 was also shown to inhibit
proteoglycan (PG) synthesis and to promote their degra-
dation in the same species, it is not surprising that NO
was demonstrated to participate in cartilage damage on
the following basis: (i) an apparent inverse relationship
between NO production and PG synthesis; (ii) a restoration
of PG synthesis when lowering NO production by NOS
inhibitors; (iii) an ability of NO gas or NO donors to mimic
IL-1 effect on PG synthesis. However, the ability of NOS
inhibitors to correct PG synthesis inhibition was reported
as total,7 partial8 or even absent.9 This difference was
ascribed to species differences with bovine being solely
unresponsive.9 More recently, it has been proposed that a
partial correcting effect may result from heterogeneity of
cartilage cells because chondrocytes had different meta-
bolic responses depending on the layer they originated
from.10 Our results suggest that the effect of NOS inhibitors
on PG synthesis is also strongly influenced by the extra-
cellular matrix since the full correction we observed with
alginate beads failed to be confirmed consistently with
patellae. Whether this reflects simply an easier diffusion
of compounds towards cells or involves more complexintegrin-mediated events11 requires further studies. In all
cases, although L-arg analog inhibitors were somewhat
less potent than isothioureas in reducing nitrite levels, they
were much more efficient in restoring PG synthesis
especially in patellae. These results are consistent with a
previous finding from Jang et al.12 with bovine chondro-
cytes but suggest that isothioureas may be of limited value
for sparing cartilage perhaps due to poor cellular uptake
within extracellular matrix. In addition, our data confirm that
NO accounts importantly for IL-1 induced inhibition of
cartilage anabolism in rat.
As in-vivo NO may originate from cartilage but also from
menisci and synovium, particularly when inflamed in the
course of RA or OA,11 we further compared L-NMMA and
SMT in the IL-1 arthritis model. Although IL-1 was reported
to be poorly retained in the knee joint, a single ia injection
was sufficient to decrease significantly PG synthesis in
rodents13 whatever cellular infiltration by polymorpho-
nuclear cells. Thus, the IL-1 arthritis model is well adapted
to study the chondroprotective effects of drugs. In our
experiment, the suppressive effect of IL-1 on PG synthesis
was maximal 2 days after injection, which is in good
accordance with previous reports in mouse,13,14 whereas
NO production peaked in synovial fluid by 6 to 10 h. These
results suggest that NO may act as an early mediator of
IL-1 effect and this was also observed in the more
sustained arthritis induced by zymosan.14 When injected
together with IL-1, L-NMMA significantly reduced
NO2− +NO3− levels in all joint tissues including synovial
fluid and this led to partial restoration of PG synthesis,
suggesting that NO inhibition may promote ‘chondroprotec-
tion’. We must keep in mind that several non-specific
actions have been reported for L-NMMA4 and this was one
of the main reasons for testing the small non-amino acid
based inhibitor SMT. Unfortunately, SMT was ineffective,
a finding which was not unexpected on the basis of
our in-vitro assay with patellae but may reflect a limited
bioavailability. We did not assess PG degradation and
it remains to be seen whether NOS inhibitors are not
able to trigger PG loss from rat cartilage. However, in
light of recent finding with NOSII knock-out mice,14 it
can be proposed that maintaining PG synthesis might
be sometimes sufficient to compensate for enhanced PG
loss. We showed that L-NMMA has chondroprotective
potency even after a single ia injection and we hypothesize
that this might be due to its rapid uptake by joint
tissues. This is interesting when considering that
any systemic administration of L-NMMA would generate
Osteoarthritis and Cartilage Vol. 7 No. 4 385hypertension, and leads us to suggest that its sustained
delivery within joints may be worth of study. The latter does
not exclude the promising systemic use of highly selective
NOS inhibitors subject to those will be adequately uptaken
by joint tissues, as N-iminoethyl-L-lysine in experimental
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